Home › Understand › Questions and answers
Questions and answers
60 questions people actually ask, answered plainly. Every answer links to the source it came from, so you can check any of it.
These answers explain what is known. They are not medical advice and they cannot tell you what is happening to one particular person — that conversation belongs with the treating doctor. If you need to talk to somebody now, the Alzheimer's Association helpline is 1-800-272-3900, free, 24 hours a day, in English and Spanish.
Basics
What is Alzheimer's disease?
Alzheimer's is a physical brain disease. The National Institute on Aging describes it as “a brain disorder that slowly destroys memory and thinking skills, and eventually, the ability to carry out the simplest tasks.” The damage starts in the parts of the brain that form new memories — the hippocampus and entorhinal cortex — and spreads outward as more brain cells stop working and die. It is the most common cause of dementia in older adults.
Two abnormal protein build-ups, amyloid plaques and tau tangles, are considered hallmarks of the disease, along with the loss of connections between brain cells. (NIA Alzheimer's Disease Fact Sheet)
What's the difference between Alzheimer's and dementia?
Dementia is the umbrella term, not a specific disease. The NIA defines it as “the loss of cognitive functioning — thinking, remembering, and reasoning — and behavioral abilities to such an extent that it interferes with a person's daily life and activities.” Alzheimer's is one cause of dementia; others include Lewy body dementia, frontotemporal disorders and vascular dementia, and it is common for a person to have more than one type at once (“mixed dementia”).
Worldwide, the World Health Organization estimates Alzheimer's disease “may contribute to 60–70% of cases” of dementia. (NIA) (WHO dementia fact sheet, updated 3 July 2026)
Is forgetting things just a normal part of getting older?
Some of it is. The NIA's own answer is that “forgetfulness can be a normal part of aging, but Alzheimer's and related dementias are not.” The difference it draws is about daily life: ordinary forgetfulness does not stop you doing things, while “serious memory problems, such as those that occur with Alzheimer's, make it hard to do everyday tasks” such as driving, cooking and shopping.
The CDC makes the same point about dementia generally — though it “mostly affects older adults, it is not a part of normal aging.” If the forgetfulness is worrying you, that in itself is a reason to raise it with a doctor. (NIA) (CDC)
How many people have Alzheimer's?
In the United States, the Alzheimer's Association's 2026 Facts and Figures report estimates that 7.4 million Americans age 65 and older are living with clinical Alzheimer's dementia, and projects that this could reach 13.8 million by 2060. Those are modelled estimates built from population studies, not a headcount of diagnosed people, so treat them as best available estimates rather than measured totals.
Globally, the WHO reported 57 million people living with dementia of all causes in 2021, with nearly 10 million new cases a year. (2026 Alzheimer's Disease Facts and Figures) (WHO, 2026)
Is Alzheimer's actually fatal, or do people die of something else?
Both things are true. Facts and Figures 2026 states plainly that “Alzheimer's disease is ultimately fatal, although many people with Alzheimer's die of other common, coexisting conditions of older age.” In the late stage the body itself shuts down; pneumonia and other complications are common immediate causes.
On death certificates, 116,022 U.S. deaths were officially recorded from Alzheimer's in 2024, making it the sixth-leading cause of death in the United States that year and the fifth-leading cause among people 65 and older. (Facts and Figures 2026, reporting 2024 NCHS data)
How long do people live after a diagnosis?
There is no reliable individual answer, and anyone who gives you one is guessing. Across studies, people age 65 and older survive an average of four to eight years after a diagnosis of Alzheimer's dementia — but some live as long as 20 years. Facts and Figures 2026 attributes that wide spread to “the slow, insidious and uncertain progression of Alzheimer's.”
One figure worth knowing when planning: a person who lives from age 70 to age 80 with Alzheimer's dementia spends on average about 40% of that time in the severe stage. (Facts and Figures 2026)
What causes Alzheimer's?
Honestly: nobody fully knows. The NIA's position is that “scientists don't yet fully understand what causes Alzheimer's disease in most people,” and that the causes probably involve a combination of age-related brain changes with genetic, environmental and lifestyle factors, weighted differently from person to person.
What is well established is what the disease looks like in the brain — amyloid plaques, tau tangles, inflammation, blood vessel damage and the death of neurons, with changes beginning a decade or more before any symptoms appear. It is not caused by anything the person did wrong. (NIA) (NIA: What Causes Alzheimer's Disease?)
Symptoms & stages
What are the earliest signs?
Memory trouble is typically — but not always — first. The NIA notes that “memory problems are typically one of the first signs of cognitive impairment related to Alzheimer's,” but adds that for many people the earliest stage shows up as decline in non-memory thinking: trouble finding words, problems judging where objects are in space or how far away they are, and impaired reasoning or judgment.
Because the first symptoms vary this much from person to person, a change in how someone manages ordinary tasks matters more than any single symptom. (NIA) (NIA: What Are the Signs of Alzheimer's Disease?)
How do I tell a warning sign from ordinary forgetting?
The test the NIA applies is interference with everyday tasks. Losing your keys or a name and recovering it later is common; being unable to manage driving, cooking or shopping is not. As Alzheimer's progresses, “a person with Alzheimer's may not remember important places, dates, events, or even their family.”
Some early Alzheimer's changes are not memory at all — repeating questions, taking much longer over routine tasks, getting lost in familiar places, trouble handling money and bills, and shifts in personality and behavior. (NIA, 10 Frequently Asked Questions)
What are the stages, and what happens in each?
The NIA uses three broad stages. In mild Alzheimer's, people have greater memory loss plus problems such as wandering and getting lost, difficulty handling money and paying bills, repeating questions, taking longer over normal tasks, and personality changes — this is when most people are diagnosed. In moderate Alzheimer's, damage reaches areas controlling language, reasoning and sensory processing; people begin having trouble recognizing family and friends, may be unable to learn new things or carry out multi-step tasks like getting dressed, and may have hallucinations, delusions and paranoia.
In severe Alzheimer's, plaques and tangles are widespread, brain tissue has shrunk significantly, and people cannot communicate and are completely dependent on others. (NIA Alzheimer's Disease Fact Sheet)
What is mild cognitive impairment, and does it always turn into Alzheimer's?
No, it does not always. MCI means someone has more memory or thinking problems than is normal for their age, but the symptoms do not yet interfere with everyday life. The NIA reports that an estimated 10–20% of people age 65 or older with MCI develop dementia over a one-year period — which also means most do not, in any given year.
The NIA is explicit that “not everyone who has MCI develops dementia. In many cases, the symptoms of MCI may stay the same or even improve.” Researchers still do not know why some people progress and others do not. (NIA: What Is Mild Cognitive Impairment?)
What happens in the last stage?
In late-stage Alzheimer's the person cannot communicate and depends completely on others for care. The NIA notes that near the end of life a person may be in bed most or all of the time as the body shuts down, and that caregiving shifts toward preventing pressure sores, helping with movement, managing swallowing problems and keeping the person comfortable.
One thing worth knowing in advance: a person in the final stages may be unable to tell you they are in pain, and may instead express it through groans, sighs, grimacing when touched, or becoming upset or aggressive. (NIA) (NIA: Care in the Last Stages of Alzheimer's Disease)
What is sundowning, and why does it happen in the evening?
Sundowning is a pattern of increased agitation, confusion or restlessness in the late afternoon and evening, and it is common enough that the NIA treats it alongside agitation and aggression as a core caregiving topic. The honest position is that the underlying cause is not settled; what is documented is a set of triggers worth ruling out first.
Because agitation can also be driven by pain, medication side effects, infection, poor sleep or an over-stimulating environment, a sudden change in behavior is a reason to call the doctor rather than to assume it is “just the dementia.” (NIA: Coping With Agitation, Aggression, and Sundowning)
Diagnosis & testing
How is Alzheimer's diagnosed?
There is no single test. Doctors put together a medical history, questions about daily life and behavior, cognitive testing, a physical and neurological exam, and blood and imaging tests — partly to look for Alzheimer's, and partly to rule out other causes. The NIA lists thyroid disease, sleep disturbances, medication side effects, infection and other dementias among conditions that can look similar, and notes that “some of these conditions may be treatable and possibly reversible.”
It is no longer true that Alzheimer's can only be confirmed after death: the NIA states that before the early 2000s autopsy was the only sure way, but lab and imaging tests can now show biological signs of the disease in a living person. (NIA: How Is Alzheimer's Disease Diagnosed?)
Is there a blood test for Alzheimer's now?
Yes, one exists, but it is narrower than the headlines suggested. On 16 May 2025 the FDA cleared the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio — the first blood-based in vitro diagnostic “to aid in diagnosing Alzheimer's disease.” It measures two proteins in plasma and calculates a ratio that correlates with the presence or absence of amyloid plaques.
Important limits in the clearance itself: it is for adults aged 55 and older who already have signs and symptoms of the disease, and it is an aid to diagnosis, not a standalone answer or a screening test for healthy people. (FDA news release, 16 May 2025)
Will I need a PET scan or a spinal tap?
Not necessarily. Amyloid PET scans can show plaques in a living brain, and spinal fluid tests obtained by lumbar puncture can measure the same proteins, but the FDA notes PET is “a costly and time-consuming option” that exposes patients to radiation, and that the newer blood test reduces the need for it.
Which tests you are offered depends on the question being asked, what is available where you live, and — in practice — whether the result would change anything. Confirmation of amyloid is required before starting an anti-amyloid drug, so that is the situation where it most often comes up. (FDA) (NIA: How Biomarkers Help Diagnose Dementia)
Should older adults with no symptoms be screened for memory problems?
This is a genuinely unresolved question, and the official U.S. answer is “we don't know.” The U.S. Preventive Services Task Force concluded that “the current evidence is insufficient to assess the balance of benefits and harms of screening for cognitive impairment in older adults” — an I statement, meaning neither for nor against. It applies to community-dwelling adults 65 and older without recognized signs or symptoms.
That recommendation was finalized on 25 February 2020 and the USPSTF lists the topic as being updated. It says nothing about people who do have symptoms — if there are symptoms, that is evaluation, not screening. (USPSTF final recommendation statement)
Does Medicare pay for a memory evaluation?
Medicare Part B covers a separate visit for a cognitive assessment, billed on its own rather than squeezed into another appointment. It is covered after the Part B deductible, and the visit can include a care plan to help address and manage your symptoms.
If a doctor tells you there is no way to get memory concerns properly evaluated, this is the benefit worth naming. (Medicare.gov: Cognitive assessment & care plan services)
Treatment
Is there a cure?
No. The NIA's answer is direct: “While there is no cure for Alzheimer's, there are medications available to treat the disease.” Facts and Figures 2026 puts it the same way — there is no proven way to prevent Alzheimer's and no cure, though treatments exist for symptoms and two drugs now change the underlying biology and slow progression.
The NIA also warns about the gap that desperation opens: “Check with your doctor before taking any treatment or supplement that promises to prevent or cure Alzheimer's. These ‘treatments’ might be unsafe, a waste of money, or both.” (NIA) (Facts and Figures 2026)
What do donepezil and memantine actually do?
They treat symptoms; they do not stop the disease. Donepezil, rivastigmine, galantamine and benzgalantamine are cholinesterase inhibitors prescribed for mild to moderate Alzheimer's, and the NIA says they “may help reduce or control some cognitive and behavioral symptoms” by preventing the breakdown of acetylcholine.
Memantine, for moderate to severe Alzheimer's, works differently — on glutamate — and can be combined with a cholinesterase inhibitor. The NIA's example of realistic benefit is concrete: memantine “may help a person in the later stages of the disease maintain their ability to use the bathroom independently for several more months.” (NIA: How Is Alzheimer's Disease Treated?)
What are lecanemab (Leqembi) and donanemab (Kisunla), and who can take them?
They are antibody infusions that clear beta-amyloid from the brain — the first treatments that change the underlying biology of Alzheimer's rather than only its symptoms. Both FDA labels say treatment “should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials,” and elevated brain amyloid has to be confirmed first.
That means they are not for moderate or severe Alzheimer's, and not for people whose memory problems have another cause. Donanemab is given as an intravenous infusion every four weeks; lecanemab is given intravenously or, in newer formulations, by subcutaneous injection. (Leqembi prescribing information) (Kisunla prescribing information) (FDA)
How much difference do the new drugs actually make?
A real but modest one, measured over 18 months. In its pivotal trial (NCT03887455), lecanemab reduced decline on the CDR-SB rating scale by 0.45 points versus placebo — reported in the label as 27% less decline. Donanemab's trial (NCT04437511) showed a 2.92-point difference on the iADRS scale at 76 weeks in the combined study population.
What this is not is an improvement: both groups got worse, and the treated group got worse more slowly. Facts and Figures 2026 frames the practical meaning as people staying in earlier stages longer, and cites an analysis suggesting lecanemab may extend independence in daily activities by about 10 months and donanemab by about 13 months. (Leqembi label) (Kisunla label) (Facts and Figures 2026)
What is ARIA, and how risky are these drugs?
ARIA — amyloid-related imaging abnormalities — is brain swelling (ARIA-E) or small bleeds and iron deposits (ARIA-H) seen on MRI, and both drugs carry a boxed warning about it. The FDA labels report ARIA-E in 13% of lecanemab patients versus 2% on placebo, and in 24% of donanemab patients versus 2% on placebo. The labels state that ARIA “is usually asymptomatic, although serious and life-threatening events can occur” and that ARIA can be fatal.
Risk is strongly tied to genetics: among lecanemab-treated patients, ARIA occurred in 45% of APOE ε4 homozygotes versus 13% of non-carriers, which is why both labels advise APOE ε4 testing before starting. A meta-analysis of 6,315 people receiving anti-amyloid treatment found pooled ARIA-E of 9.5% and ARIA-H of 17.5%. (Leqembi label) (Kisunla label) (Facts and Figures 2026)
Is there anything for agitation and aggression?
There is one FDA-approved option, and a real caution attached to it. On 11 May 2023 the FDA approved Rexulti (brexpiprazole) for agitation associated with dementia due to Alzheimer's — the first approved treatment for that indication — based on two 12-week placebo-controlled trials measuring change in a caregiver-rated agitation score.
Brexpiprazole is an atypical antipsychotic, and Facts and Figures 2026 notes that this class “has been associated with an increased risk of stroke and death in older people with dementia-related psychosis,” adding that “non-drug interventions should always be implemented first.” Sudden agitation is also worth checking for pain, infection or medication effects before it is treated as a behavior. (FDA news release) (Facts and Figures 2026)
Does coconut oil help with Alzheimer's?
The honest answer is that it has never been tested. The idea comes from caprylic acid, a medium-chain fat produced by processing coconut or palm kernel oil, which the body converts into ketone bodies — a possible alternative fuel for brain cells that have lost the ability to use glucose. Caprylic acid was tested as Ketasyn and sold as the medical food Axona; coconut oil became the cheap over-the-counter substitute.
The Alzheimer's Association states it plainly: a few people have reported that coconut oil helped, “but there's never been any clinical testing of coconut oil for Alzheimer's, and there's no scientific evidence that it helps.” That is not the same as “it has been disproven” — it means nobody has done the study. (Alzheimer's Association: Alternative Treatments)
Does ginkgo biloba prevent or slow dementia?
No — and this one has been properly tested, which makes the answer stronger than for most supplements. The National Center for Complementary and Integrative Health states that ginkgo “has not been shown to be beneficial for preventing or slowing the progression of dementia,” and that in three large studies of older adults with normal cognition or mild cognitive impairment, ginkgo extract did not reduce the risk of dementia.
The largest was the Ginkgo Evaluation of Memory (GEM) study: more than 3,000 people aged 75 or older, randomly assigned to ginkgo or placebo for a median of six years, with no difference between the groups in rates of dementia or Alzheimer's. (NCCIH: Ginkgo) (Alzheimer's Association)
What about vitamin E, omega-3s, and the supplements sold for memory?
The evidence is weak to negative, and it differs by supplement rather than being uniformly “unproven.” For vitamin E, the NIH Office of Dietary Supplements concludes that “most research results do not support the use of vitamin E supplements by healthy or mildly impaired individuals to maintain cognitive performance or slow its decline”; a trial in 769 people with mild cognitive impairment found no difference in progression to Alzheimer's between 2,000 IU/day vitamin E and placebo. Huperzine A was tested in a U.S. trial and gave no greater benefit than placebo.
Two structural cautions matter more than any single product. Supplements do not go through the FDA's drug review process, so what is on the label is the manufacturer's responsibility — and they can interact seriously with prescribed medicines. Tell your doctor what you are taking. (NIH Office of Dietary Supplements: Vitamin E) (Alzheimer's Association) (NIA)
Risk & prevention
Can I prevent Alzheimer's?
No one can promise you that, and the honest answer is that nothing has been proven to prevent it. The NIA's wording is careful and worth quoting: “while nothing has yet been proven to prevent Alzheimer's, researchers are studying promising strategies and learning more about what might — and might not — work.” Facts and Figures 2026 says the same: “there is no proven way to prevent Alzheimer's disease.”
The most rigorous U.S. review of the evidence, by the National Academies of Sciences, Engineering, and Medicine, found “encouraging but inconclusive” evidence for exactly three things: blood pressure management in people with high blood pressure, increased physical activity, and cognitive training. “Encouraging but inconclusive” is the real state of the science — not proof, and not nothing. (NIA) (NIA: Preventing Alzheimer's Disease — What Do We Know?) (Facts and Figures 2026)
Which risk factors can I actually change?
The 2024 report of the Lancet Commission on dementia prevention, intervention and care identified 14 modifiable risk factors which, if eliminated, might prevent nearly half of dementia cases worldwide: lower education, vision loss, high cholesterol, head injury, physical inactivity, smoking, excessive alcohol consumption, high blood pressure, obesity, diabetes, hearing loss, depression, infrequent social contact and air pollution.
Two cautions. That “nearly half” is a modelled population estimate of what might happen if entire risk factors vanished from a population — it is not a 50% cut in one person's personal risk. And a large U.S. study of more than 375,000 participants put the figure lower, estimating about 37% of dementia cases were associated with eight modifiable factors, led by midlife obesity, physical inactivity and low educational attainment. (Facts and Figures 2026, summarizing the 2024 Lancet Commission)
Does exercise help?
It is one of only three interventions the NASEM review rated as having “encouraging but inconclusive” evidence for preventing cognitive decline and dementia — which means promising, with more trial results still needed. The NIA's framing is that physical activity reduces falls, maintains mobility and independence, and promotes heart health, and lowers the risk of depression, diabetes, high blood pressure and stroke, “health conditions that can contribute to age-related cognitive decline.”
So the case for moving is strong on its own terms and plausible but unproven for dementia specifically. That is still a better bet than any supplement on the shelf. (NIA)
Does controlling blood pressure make a difference?
This has the strongest trial evidence of anything in the prevention column. SPRINT-MIND, which followed more than 8,000 adults aged 50 and older at high cardiovascular risk, found that lowering systolic blood pressure below 120 mmHg rather than the standard 140 mmHg significantly reduced the risk of mild cognitive impairment, and brain scans showed slower build-up of white matter lesions.
The picture is not uniform, though: an observational study of more than 17,000 adults found higher systolic pressure associated with lower dementia risk in people aged 60 to 70, inconsistent with SPRINT-MIND, and the NIA says this points to a need for more research on how blood pressure relates to dementia risk at different ages. Blood pressure targets are a conversation for your own doctor. (NIA)
Is there a diet that prevents Alzheimer's?
Not a proven one. The NIA answers the question directly: the NASEM review of research “did not find enough evidence to recommend a certain diet,” although some healthy eating patterns have been associated with cognitive benefits in observational studies.
Association is not the same as prevention — people who eat well differ from people who do not in many other ways. A heart-healthy eating pattern is defensible on cardiovascular grounds alone, and several of the modifiable dementia risk factors (blood pressure, cholesterol, diabetes, obesity) run through diet. (NIA) (Facts and Figures 2026)
Do hearing aids reduce dementia risk?
Possibly, for some people. Hearing loss is one of the 14 modifiable risk factors the Lancet Commission identified. The ACHIEVE study reported that hearing aid use slowed cognitive decline among people with hearing loss who were at increased risk for dementia — a finding in a higher-risk subgroup, not a promise for everyone.
Researchers are still arguing about why hearing loss and dementia travel together: it may be social isolation, it may be that hearing loss is an early manifestation of the brain changes themselves, or both. Either way, treating hearing loss improves daily life now, which is a reason that does not depend on the dementia question being settled. (Facts and Figures 2026)
Why do more women than men have Alzheimer's?
Almost two-thirds of Americans with Alzheimer's are women. Of the 7.4 million people age 65 and older with clinical Alzheimer's dementia in the U.S., 4.5 million are women and 2.9 million are men — 13% of women and 10% of men in that age group (2026 estimates).
Age is the largest part of the explanation: older age is the greatest risk factor and women live longer. Estimated lifetime risk at age 45 has been put at about 1 in 5 (20%) for women and 1 in 10 (10%) for men. Whether anything beyond longevity contributes is still being researched. (Facts and Figures 2026)
Genetics
My mother had Alzheimer's. Will I get it too?
Not necessarily — but your risk is higher than average, and that is worth saying plainly rather than softening. The NIA's answer: “people with a parent or sibling diagnosed with Alzheimer's are more likely to develop the disease,” because families share genetics, environment and lifestyle. It immediately adds the two facts people need: “not everyone with a history of Alzheimer's in their family will develop the disease,” and “not everyone who has Alzheimer's will have a family history of the disease.”
For the common late-onset form there is no single gene that decides it. Facts and Figures 2026 notes that having a parent with Alzheimer's dementia raises risk independently of known genetic risk factors such as APOE ε4 — meaning family history captures something beyond the genes we can currently test. (NIA) (Facts and Figures 2026)
What is APOE ε4, and how much does it raise my risk?
APOE is a gene that comes in several forms: ε2 appears somewhat protective, ε3 is the most common and considered neutral, and ε4 increases risk — more so with two copies than one. Facts and Figures 2026 gives concrete numbers from European and U.S. studies: among people aged 65–69, the risk of developing dementia by their early-to-mid 80s was 5–7% with no ε4 copies, 15–16% with one copy, and 31–40% with two.
Read those numbers carefully. Even two copies of ε4 — the highest-risk common genotype — left the majority of people in those studies without dementia by their mid-80s. APOE ε4 shifts the odds; it does not settle the outcome. (Facts and Figures 2026) (NIA Genetics Fact Sheet)
Should I get genetic testing for Alzheimer's?
For most people, no. The NIA states that genetic tests “are not routinely used in clinical settings to diagnose or predict the risk of developing Alzheimer's or a related dementia.” Testing for APP, PSEN1 and PSEN2 may be ordered by a specialist in a specific situation: symptoms at an early age together with a strong family history.
APOE testing is available but, in the NIA's words, “the results cannot fully predict who will or won't develop Alzheimer's”; it is used mainly in research settings. One exception has emerged in treatment: both anti-amyloid drug labels advise APOE ε4 testing before starting, because it predicts the risk of brain swelling side effects. If you are considering testing, ask for a genetic counsellor first. (NIA Genetics Fact Sheet) (Facts and Figures 2026)
Is early-onset Alzheimer's inherited?
Sometimes, and this is the one situation where a single gene really can decide it. Rare inherited variants in three genes — APP, PSEN1 and PSEN2 — give a child of a carrier a 50/50 chance of inheriting the variant, and if inherited, “a very strong probability of developing Alzheimer's before age 65 and sometimes much earlier.”
But this accounts for a small slice of a small group. Fewer than 10% of all people with Alzheimer's develop symptoms before 65, and of those, only 10–15% can be attributed to changes in APP, PSEN1 or PSEN2. Most early-onset Alzheimer's is not explained by these genes. (NIA Genetics Fact Sheet) (Alzheimer's Association: Younger/Early-Onset Alzheimer's)
Why do people with Down syndrome develop Alzheimer's so often?
Because of a gene dose effect. People with Down syndrome are born with an extra copy of chromosome 21, which carries the APP gene. Too much APP protein leads to a build-up of beta-amyloid plaques in the brain. The NIA estimates that 50% or more of people living with Down syndrome will develop Alzheimer's, with symptoms typically appearing in their 50s and 60s.
“Many but not all” is the NIA's phrasing, and it matters — this is a substantially raised risk at younger ages, not a certainty. (NIA Genetics Fact Sheet) (NIA: Alzheimer's Disease in People With Down Syndrome)
My consumer DNA test says I carry APOE ε4. What should I do with that?
Take it seriously as information about probability, and not as a diagnosis or a prediction. The NIA's assessment of APOE testing applies regardless of who performed it: “the results cannot fully predict who will or won't develop Alzheimer's.” Carrying ε4 does not mean you will get Alzheimer's, and not carrying it does not mean you won't.
Two things it is reasonable to do: talk it through with a doctor or genetic counsellor rather than sitting with it alone, and note that the risk factors you can act on — blood pressure, hearing, activity, smoking, diabetes — are the same whatever your APOE result. (NIA Genetics Fact Sheet) (NIA: Thinking About Your Risk for Alzheimer's Disease?)
Caregiving
She accuses me of stealing things. Why, and what do I do?
This is one of the most common and most painful behaviors, and it is the disease talking. The NIA lists “hiding things or believing other people are hiding things” and “feeling suspicious of or threatened by others, for little or no reason” among the common behavior changes in Alzheimer's, and asks caregivers to remember that “the disease, not the person with Alzheimer's, causes these changes.”
Before treating it as a fixed symptom, check for other drivers the NIA names: emotions such as fear or anxiety, pain, lack of sleep, trouble seeing or hearing, constipation, hunger or thirst, and side effects of new medications. Any of those can be fixed; arguing about where the purse went cannot. (NIA: Managing Personality and Behavior Changes)
Should I correct him when he says something that isn't true?
Usually not. Alzheimer's makes finding words, understanding meaning, following long conversations and holding a train of thought progressively harder, so correction adds difficulty to a conversation that is already hard. The NIA's advice is to be aware of your tone, volume, facial expression and body language, and to “try to avoid appearing angry or tense. Show a warm, loving, and matter-of-fact manner.”
For angry outbursts specifically, the NIA suggests patience, distraction such as a favorite snack or a walk outside, and stepping away to calm down if you become frustrated. Note too that people diagnosed earlier are often aware of their own changes and may want to talk about them — when that happens, listening matters more than accuracy. (NIA: Communicating With Someone Who Has Alzheimer's)
When should someone with dementia stop driving?
There is no single milestone, and some people with early dementia can still drive safely for a while. The NIA's standard is functional: “good drivers are alert, think clearly, and make good decisions quickly. When someone with Alzheimer's is not able to do these things, it's time to stop driving.” The specific risk it names is reaction to the unexpected — someone may drive fine on a familiar route and be unable to respond to a surprise.
The NIA's practical advice is to start the conversation early, before it is urgent, so there is time to line up other transportation. That is easier to do at the start than in the middle of an argument after a near-miss. (NIA: Driving Safety and Alzheimer's Disease)
I need a break. What help actually exists?
Respite care is the name for it: short-term care at home, in a facility, or at an adult day center, lasting “anywhere from a few hours to several weeks at a time.” It is a planned tool, not a last resort. The federal National Family Caregiver Support Program funds respite along with counseling, support groups, training and help finding services, through state and local agencies.
Eligibility is broader than people expect: the program explicitly covers caregivers of “individuals of any age with Alzheimer's disease and related disorders,” not just those over 60. The Eldercare Locator (1-800-677-1116) will connect you to the agency in your area. (NIA: Getting Help With Alzheimer's Caregiving) (ACL: National Family Caregiver Support Program) (Eldercare Locator)
I'm exhausted and resentful. Is something wrong with me?
No. In 2025, 12.7 million family and other unpaid caregivers provided an estimated 19.6 billion hours of care to people with Alzheimer's or other dementias — an average of nearly 30 hours per caregiver per week, on top of everything else. Fifty-nine percent of family caregivers of people with Alzheimer's or other dementias rated the emotional stress of caregiving as high or very high.
Seventy-four percent reported being somewhat to very concerned about maintaining their own health since becoming a caregiver. The NIA's response is not willpower but structure: ask for help in specific ways, join a support group in person or online, use home health or adult day services, and take breaks each day. (Facts and Figures 2026) (NIA: Alzheimer's Caregiving — Caring for Yourself)
Can someone with early-stage dementia live alone?
Many do, at least for a time. The NIA has a whole guide for people living alone with early-stage dementia, built around making everyday tasks easier, scanning the home for safety risks, planning ahead while decisions can still be made, strengthening a support system, and looking after physical and mental health.
It is a situation that needs reviewing, not deciding once. The abilities that make living alone workable — judgment, reacting to the unexpected, managing money and medication — are exactly the ones the disease erodes, so what is safe this year may not be next year. (NIA: Tips for Living Alone With Early-Stage Dementia)
Costs & insurance
Does Medicare pay for a nursing home or long-term care?
No, and this is the single most common and most expensive misunderstanding in dementia care. Medicare.gov states flatly that “Medicare doesn't pay for long-term care” — you pay all costs. Long-term care, also called custodial care, means help with the basic tasks of daily life — dressing, bathing, using the bathroom, meals, adult day health care, transportation — and it is different from skilled nursing facility care, which Medicare does cover in limited circumstances.
Because most long-term care is non-medical, Medicare and most health insurance including Medigap do not pay for it, whether it is delivered in a nursing home or at home. A 2022 survey found 23% of adults believed Medicare would cover nursing home costs and another 28% were not sure who would pay. (Medicare.gov: Long-term care) (Facts and Figures 2026)
What does care actually cost?
These are the 2024 national medians and averages reported in Facts and Figures 2026 (2025-dollar equivalents in brackets): a non-medical home health aide cost $34 per hour and $6,483 per month [$35 and $6,688], adult day services $100 per day [$104], and an assisted living residence $5,900 per month, or $70,800 per year [$6,141 and $73,694].
Nursing homes: an average of $305 per day, or $111,325 per year, for a semi-private room and $350 per day, or $127,750 per year, for a private room [$115,876 and $132,972]. Nationally, total payments in 2026 for health care, long-term care and hospice for people 65 and older with dementia are estimated at $409 billion, of which out-of-pocket spending is expected to be $103 billion, or 25%. (Facts and Figures 2026)
We can't afford this. Who pays?
For long-term care, the honest answer is mostly Medicaid or you. Medicaid covers long-term nursing home stays, but only for people who meet its income and asset limits, and what is covered varies substantially by state — in 2022, home- and community-based services ranged from 32% of Medicaid long-term care spending in Mississippi to 84% in Oregon.
The NIA's list of other places to look is worth working through: Medicare for what it does cover, Medicaid, PACE (Program of All-Inclusive Care for the Elderly), your State Health Insurance Assistance Program for free counselling, the Department of Veterans Affairs, and Social Security. Start with the Eldercare Locator on 1-800-677-1116. (NIA: Paying for Long-Term Care) (Facts and Figures 2026)
Does Medicare cover the new anti-amyloid drugs?
Yes, with conditions. Under national coverage determination 200.3, effective 7 April 2022, CMS covers FDA-approved monoclonal antibodies directed against amyloid for Alzheimer's under coverage with evidence development — for patients with a clinical diagnosis of mild cognitive impairment due to Alzheimer's or mild Alzheimer's dementia, with confirmed amyloid pathology.
“Coverage with evidence development” means participation in a CMS-approved study or registry is part of the deal, and data on outcomes is collected. Coverage of the drug is also separate from the cost of the required MRI monitoring, amyloid confirmation and infusion visits, so ask what the full year looks like. (CMS NCD 200.3)
He's 58 and can't work. Can he get disability?
Possibly, and faster than most claims. Social Security's Compassionate Allowances program identifies conditions that so clearly meet disability standards that claims can be fast-tracked, and “Young-Onset Alzheimer's Disease” is on the published list of conditions.
Being on the list does not approve a claim by itself — medical evidence is still required — but it means the application should not sit in the ordinary queue. (SSA: Compassionate Allowances, complete list of conditions)
Is there any Medicare help aimed at caregivers?
Yes — through the GUIDE Model, a Medicare dementia care model run by the CMS Innovation Center. Participating programs provide care navigation, 24/7 access to a support line, caregiver training and education, respite services of up to $2,500 annually, and connections to community resources.
It is a model programme, not a universal benefit, so availability depends on whether a participating organization operates near you — worth asking the neurologist or primary care practice directly. (CMS: Guiding an Improved Dementia Experience (GUIDE) Model)
Research & trials
How do I find a clinical trial?
The NIA points to four routes: talk to your own health care provider about local studies; search the Alzheimers.gov Clinical Trials Finder or sign up for email alerts; join a registry or matching service so you can be invited to studies; or contact an NIA-funded Alzheimer's Disease Research Center or a memory or neurology clinic near you.
ClinicalTrials.gov, run by the U.S. National Library of Medicine, is the underlying public registry and can be searched directly by condition and location. (NIA Alzheimer's Disease Fact Sheet) (ClinicalTrials.gov)
How much Alzheimer's research is actually going on?
A query of the ClinicalTrials.gov API on 23 September 2026 for the condition “Alzheimer Disease” returned 4,289 registered studies in total, of which 628 were listed as currently recruiting. These are measured registry counts on that date, not projections, and they include observational studies as well as drug trials.
The number is large partly because most candidate treatments fail. That is the ordinary shape of drug development, not a sign that nothing is happening. (ClinicalTrials.gov API, retrieved 23 September 2026)
Can I join a study if I don't have Alzheimer's?
Yes. The NIA is explicit: “everybody — those with Alzheimer's or mild cognitive impairment as well as healthy volunteers with or without a family history of Alzheimer's — may be able to take part in clinical trials and studies.” Studies of healthy volunteers are how researchers learn what normal brain aging looks like, which is what abnormal is measured against.
The NIA also notes that researchers need participants of different ages, sexes, races and ethnicities so that results actually apply to the people who get the disease — under-representation is a real and acknowledged problem in this field. (NIA) (NIA: What Are Clinical Trials and Studies?)
Is a cure close?
No one can tell you that, and we would be lying if we implied otherwise. As of the 2026 Facts and Figures report, there is no cure and no proven prevention; what has changed is that two drugs now alter the underlying biology and modestly slow decline in early disease, rather than only treating symptoms.
The NIA's honest framing is that “although there is no single medication or other intervention that will be successful for everyone, scientists continue to study promising new approaches.” Meaningful progress has happened; a cure is not in hand. (Facts and Figures 2026) (NIA)
End-of-life & late stage
When is it time for hospice?
Medicare's rule is that your hospice doctor and your regular doctor certify that you are terminally ill with a life expectancy of six months or less, you accept comfort care instead of treatment intended to cure the illness, and you sign a statement choosing hospice.
Two things families often do not know. Hospice does not end at six months — care continues as long as the hospice doctor recertifies after a face-to-face visit that the person is still terminally ill. And you have the right to change hospice provider once during each benefit period. (Medicare.gov: Hospice care)
Should we put in a feeding tube when she stops eating?
This is the hardest question on this page, and the evidence points one way. Facts and Figures 2026 states that in advanced dementia, “feeding tube placement does not prolong life or improve outcomes.” It also notes that the odds of a feeding tube being inserted at the end of life vary widely across the country in ways not explained by how ill the person is.
Careful hand feeding is the usual alternative. This is a decision to make with the person's own doctor and, where possible, with what the person said they wanted while they could still say it — which is the strongest argument for having that conversation early. (Facts and Figures 2026)
What does the end actually look like?
In the final stage, a person cannot communicate and is completely dependent on others; near the end of life they may be in bed most or all of the time as the body shuts down. Caregiving becomes physical — repositioning at least every two hours to prevent pressure sores, managing swallowing problems, keeping the person comfortable.
The NIA's most useful warning is about pain: a person in the final stages may be unable to say they are in pain, and may instead groan or sigh, grimace when touched, or become upset or aggressive. Treat a change in behavior as a possible pain signal. Hospice and palliative care programs can coordinate this care and provide referrals. (NIA) (NIA: Care in the Last Stages of Alzheimer's Disease)
How do I make decisions for someone who can't tell me what they want?
The NIA describes two recognized approaches. Substituted judgment means putting yourself in the place of the person who is dying and choosing as they would have chosen; some experts hold that decisions should be based on this whenever possible. Best interests means deciding what you, as their representative, believe is best for them, and the two are often combined.
Both work far better when there is something to go on — an advance care plan, a named health care proxy, or remembered conversations. If the person you care for can still express preferences, that conversation is the most valuable thing you can do this month. (NIA: Making Decisions for Someone at the End of Life)
Where these answers come from
Each answer is written from the sources linked underneath it — mostly the National Institute on Aging, the CDC, the FDA, CMS and published studies. Where researchers disagree or the evidence is thin, the answer says so rather than picking a side.
60 questions in 10 topics. Looking for something specific? Search the whole site.